Antifungal pharmacokinetics and pharmacodynamics

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 5, 2015, Pages

  Lepak, Alexander J ^a   Andes, David R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCYTOSINE; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; POLYENE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; HUMAN; METHODOLOGY; NONHUMAN; TREATMENT DURATION; ANIMAL; DISEASE MODEL; MOUSE; MYCOSES; RABBIT; RAT;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FLUCYTOSINE; HUMANS; MICE; MYCOSES; POLYENES; RABBITS; RATS; TRIAZOLES;

EID: 84930508300     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a019653     Document Type: Article

References (189)

1. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with pres-ence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56: 1724-1732
2. Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW. 2012. Phar- macodynamics of itraconazole against Aspergillus fumi- gatus in an in vitro model of the human alveolus: Per- spectives on the treatment of triazole-resistant infection and utility of airway administration. Antimicrob Agents Chemother 56: 4146-4153
3. Andes D. 2003a. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47: 1179-1186
4. Andes D. 2003b. Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am 17: 635-649
5. Andes D. 2004. Clinical utility of antifungal pharmacokinet- ics and pharmacodynamics. Curr Opin Infect Dis 17: 533-540
6. Andes D, van Ogtrop M. 1999. Characterization and quan- titation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43: 2116-2120
7. Andes D, van Ogtrop M. 2000. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 44: 938-942
8. Andes D, Stamsted T, Conklin R. 2001. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminat-ed-candidiasis model. Antimicrob Agents Chemother 45: 922-926
9. Andes D, Marchillo K, Stamstad T, Conklin R. 2003a. In vivo pharmacokinetics and pharmacodynamics of a new tri-azole, voriconazole, in a murine candidiasis model. Anti- microb Agents Chemother 47: 3165-3169
10. Andes D, Marchillo K, Stamstad T, Conklin R. 2003b. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47: 1193-1199
11. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R. 2003c. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47: 1187-1192
12. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cac-ciapuoti A, Loeberg D. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of dis- seminated candidiasis. Antimicrob Agents Chemother 48: 137-142
13. Andes D, Safdar N, Marchillo K, Conklin R. 2006. Pharma- cokinetic-pharmacodynamic comparison of amphoteri-cin B (AMB) and two lipid-associated AMB prepara- tions, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemo- ther 50: 674-684
14. Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J. 2008a. In vivo pharmacodynamic char-acterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52: 539-550
15. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmu- eller J. 2008b. In vivo pharmacodynamic target investi- gation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52: 3497-3503
16. Andes D, Pascual A, Marchetti O. 2009. Antifungal thera-peutic drug monitoring: Established and emerging indi- cations. Antimicrob Agents Chemother 53: 24-34
17. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo comparison of the pharmaco- dynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54: 2497-2506
18. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ; Mycoses Study Group. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of ran- domized trials. Clin Infect Dis 54: 1110-1122
19. Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM. 2013. Clinical pharmacodynamic in- dex identification for micafungin in esophageal candidi- asis: Dosing strategy optimization. Antimicrob Agents Chemother 57: 5714-5716
20. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 52: 3022-3028
21. Barchiesi F, Spreghini E, Santinelli A, Fothergill AW, Pisa E, Giannini D, Rinaldi MG, Scalise G. 2007. Posaconazole prophylaxis in experimental systemic zygomycosis. Anti- microb Agents Chemother 51: 73-77
22. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, et al. 2009. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen ver- sus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48: 1676-1684
23. Bizerra FC, Melo AS, Katchburian E, Freymuller E, Straus AH, Takahashi HK, Colombo AL. 2011. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother 55: 302-310
24. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. 1989. Antifungal prophylaxis with itraco- nazole in prolonged neutropenia: Correlation with plas- ma levels. Mycoses 32 (Suppl 1): 103-108
25. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45: 3474-3481
26. Bradley JS, Dudley MN, Drusano GL. 2003. Predicting efficacy of antiinfectives with pharmacodynamics and Mon- te Carlo simulation. Pediatr Infect Dis J 22: 982-992; quiz 993-985
27. Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. 2010. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: Selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J 29: 1043-1046
28. Brammer KW, Farrow PR, Faulkner JK. 1990. Pharmacoki-netics and tissue penetration of fluconazole in humans. Rev Infect Dis 12 (Suppl 3): S318-S326
29. Brock M, Jouvion G, Droin-Bergere S, Dussurget O, Nicola MA, Ibrahim-Granet O. 2008. Bioluminescent Aspergil-lus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis. Appl Environ Microbiol 74: 7023-7035
30. Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Shep- pard DC. 2013. Pharmacokinetics of posaconazole with-in epithelial cells and fungi: Insights into potential mech- anisms of action during treatment and prophylaxis. J Infect Dis 208: 1717-1728
31. Chandrasekar PH, Cutright JL, Manavathu EK. 2004. Effi- cacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillo- sis. Clin Microbiol Infect 10: 925-928
32. Chryssanthou E, Cuenca-Estrella M. 2006. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for suscepti- bility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect 12: 901-904
33. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. 2005. Fluconazole MIC and the fluconazole dose/ MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 49: 3171-3177
34. Clemons KV, Stevens DA. 2006. Efficacy of micafungin alone or in combination against experimental pulmonary as-pergillosis. Med Mycol 44: 69-73
35. Clemons KV, Espiritu M, Parmar R, Stevens DA. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50: 1293-1297
36. CLSI. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts: Approved guideline. Clinical and Labora-tory Standards Institute, Wayne, PA
37. CLSI. 2008a. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard, 3rd ed., No. 14. Clinical and Laboratory Standards Institute, Wayne, PA
38. CLSI. 2008b. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: Approved stan-dard, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA
39. CLSI. 2008c. Method for antifungal disk diffusion susceptibil- ity testing of filamentous fungi: Proposed guideline. Clinical and Laboratory Standards Institute, Wayne, PA
40. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, et al. 2007. Liposomal amphotericin B as initial ther- apy for invasive mold infection: A randomized trial com- paring a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44: 1289-1297
41. Cowen LE, Lindquist S. 2005. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 309: 2185-2189
42. Craig WA. 1998. Pharmacokinetic/pharmacodynamic pa- rameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1-10; quiz 11-12
43. Craig WA, Ebert SC. 1989. Protein binding and its signif- icance in antibacterial therapy. Infect Dis Clin North Am 3: 407-414
44. Craig WA, Kunin CM. 1976. Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med 27: 287-300
45. Craig WA, Vogelman B. 1987. The postantibiotic effect. Ann Intern Med 106: 900-902
46. Craig WA, Welling PG. 1977. Protein binding of antimicro- bials: Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2: 252-268
47. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. 2003. Ac- tivity of posaconazole in treatment of experimental dis-seminated zygomycosis. Antimicrob Agents Chemother 47: 3647-3650
48. Denning DW, Warn P. 1999. Dose range evaluation of lipo- somal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neu- tropenic mice infected with an isolate of Aspergillus fu- migatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother 43: 2592-2599
49. Drusano GL. 2004. Antimicrobial pharmacodynamics: Critical interactions of “bug and drug.” Nat Rev Microbiol 2: 289-300
50. Drusano GL. 2007. Pharmacokinetics and pharmacody- namics of antimicrobials. Clin Infect Dis 45 (Suppl 1): S89-S95
51. Eagle H, Musselman AD. 1949. The slow recovery of bacteria from the toxic effects of penicillin. J Bacteriol 58: 475-490
52. Elefanti A, Mouton JW, Krompa K, Al-Saigh R, Verweij PE, Zerva L, Meletiadis J. 2013. Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob Agents Chemother 57: 1625-1631
53. Eriksson U, Seifert B, Schaffner A. 2001. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 322: 579-582
54. Ernst EJ, Klepser ME, Pfaller MA. 1998. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time. Diagn Microbiol Infect Dis 32: 205-210
55. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 33: 75-80
56. Ernst EJ, Klepser ME, Pfaller MA. 2000. Postantifungal ef- fects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neofor- mans. Antimicrob Agents Chemother 44: 1108-1111
57. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. 2002a. In vitro activity of micafungin (FK-463) against Candida spp.: Microdilution, time-kill, and postanti- fungal-effect studies. Antimicrob Agents Chemother 46: 3846-3853
58. Ernst EJ, Yodoi K, Roling EE, Klepser ME. 2002b. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 46: 578-581
59. EUCAST. 2008. EUCAST Definitive Document E.Def 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden
60. EUCAST. 2012. EUCAST Definitive Document E.Def 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden
61. Fisher JF, Sobel JD, Kauffman CA, Newman CA. 2011. Can- dida urinary tract infections—Treatment. Clin Infect Dis 52 (Suppl 6): S457-S466
62. Fortwendel JR, Juvvadi PR, Perfect BZ, Rogg LE, Perfect JR, Steinbach WJ. 2010. Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Anti- microb Agents Chemother 54: 1555-1563
63. Francesconi A, Kasai M, Petraitiene R, Petraitis V, Kelaher AM, Schaufele R, Hope WW, Shea YR, Bacher J, Walsh TJ. 2006. Characterization and comparison of galacto- mannan enzyme immunoassay and quantitative real- time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 44: 2475-2480
64. Francis P, Walsh TJ. 1992. Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 15: 1003-1018
65. Galiger C, Brock M, Jouvion G, Savers A, Parlato M, Ibra- him-Granet O. 2013. Assessment of efficacy of antifungals against Aspergillus fumigatus: Value of real-time bio- luminescence imaging. Antimicrob Agents Chemother 57: 3046-3059
66. Gauthier GM, Nork TM, Prince R, Andes D. 2005. Subther- apeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41: e27-e28
67. Gavaldà J, Martín T, López P, Gomis X, Ramírez JL, Rodrí- guez D, Len O, Puigfel Y, Ruiz I, Pahissa A. 2005. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergil- losis. Clin Microbiol Infect 11: 999-1004
68. Gregson L, Hope WW, Howard SJ. 2012. In vitro model of invasive pulmonary aspergillosis in the human alveolus. Methods Mol Biol 845: 361-367
69. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ. 2000. Comparative efficacy and distribution of lipid formulations of ampho- tericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182: 274-282
70. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ. 2001. Pharmacokinet- ic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 45: 2845-2855
71. Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, Alfaro RM, Schaufele RL, Sein T, Bacher J, Walsh TJ. 2006. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formu- lations. Antimicrob Agents Chemother 50: 3418-3423
72. Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminat- ed candidiasis. Antimicrob Agents Chemother 50: 3695-3700
73. Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 51: 968-974
74. Hall P, Kennedy G, Morton J, Hill GR, Durrant S. 2005. Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infec- tion in haematology patients. Intern Med J 35: 374
75. Hong Y, Shaw PJ, Nath CE, Yadav SP, Stephen KR, Earl JW, McLachlan AJ. 2006. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 50: 935-942
76. Hope WW, Drusano GL. 2009. Antifungal pharmacokinet- ics and pharmacodynamics: Bridging from the bench to bedside. Clin Microbiol Infect 15: 602-612
77. Hope WW, Warn PA, Sharp A, Howard S, Kasai M, Louie A, Walsh TJ, Drusano GL, Denning DW. 2006. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother 50: 3680-3688
78. Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, et al. 2007a. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for anti- fungal therapy. J Infect Dis 195: 455-466
79. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. 2007b. Population pharmacokinetics of mica- fungin in pediatric patients and implications for antifun- gal dosing. Antimicrob Agents Chemother 51: 3714-3719
80. Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, et al. 2008. The pharmacokinetics and pharmacodynam- ics of micafungin in experimental hematogenous Candi- da meningoencephalitis: Implications for echinocandin therapy in neonates. J Infect Dis 197: 163-171
81. Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowiez M, Benjamin DK Jr. 2010. Population pharmacokinetics of micafungin in ne- onates and young infants. Antimicrob Agents Chemother 54: 2633-2637
82. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. 2011. Phar-macokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: Clinical implica- tions for antifungal therapy. J Infect Dis 203: 1324-1332
83. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. 2008. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 52: 1556-1558
84. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B. 2009. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 53: 772-775
85. Ikawa K, Nomura K, Morikawa N, Ikeda K, Taniwaki M. 2009. Assessment of micafungin regimens by pharmaco-kinetic-pharmacodynamic analysis: A dosing strategy for Aspergillus infections. J Antimicrob Chemother 64: 840-844
86. Imhof A, Walter RB, Schaffner A. 2003. Continuous infu- sion of escalated doses of amphotericin B deoxycholate: An open-label observational study. Clin Infect Dis 36: 943-951
87. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-re- sponse of posaconazole used for prophylaxis against in-vasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma. Clin Phar- macol Ther 88: 115-119
88. Janknegt R, de Marie S, Bakker-Woudenberg IA, Cromme- lin DJ. 1992. Liposomal and lipid formulations of am-photericin B. Clinical pharmacokinetics. Clin Pharmaco- kinet 23: 279-291
89. Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, et al. 2012a. Pharmacodynamics of vor- iconazole in a dynamic in vitro model of invasive pulmo- nary aspergillosis: Implications for in vitro susceptibility breakpoints. J Infect Dis 206: 442-452
90. Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW. 2012b. Combination of voricona-zole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 56: 5180-5185
91. Kaneko Y, Ohno H, Imamura Y, Kohno S, Miyazaki Y. 2009. The effects of an Hsp90 inhibitor on the paradoxical effect. Jpn J Infect Dis 62: 392-393
92. Kauffman CA, Frame PT. 1977. Bone marrow toxicity asso- ciated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 11: 244-247
93. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. 2002. Effi- cacy of caspofungin alone and in combination with vor-iconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 46: 2564-2568
94. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candi- da albicans. Antimicrob Agents Chemother 41: 1392-1395
95. Kunin CM, Craig WA, Kornguth M, Monson R. 1973. In- fluence of binding on the pharmacologic activity of an-tibiotics. Ann NY Acad Sci 226: 214-224
96. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-b-D-glucan synthase. Antimicrob Agents Che- mother 38: 1480-1489
97. Lee SC, Fung CP, Huang JS, Tsai CJ, Chen KS, Chen HY, Lee N, See LC, Shieh WB. 2000. Clinical correlates of an-tifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treat- ed with fluconazole. Antimicrob Agents Chemother 44: 2715-2718
98. Lengerova M, Kocmanova I, Racil Z, Hrncirova K, Pospisi- lova S, Mayer J, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF. 2012. Detection and measurement of fungal burden in a guinea pig model of invasive pulmo- nary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-b-D-glu- can detection. J Clin Microbiol 50: 602-608
99. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. 2012. Optimizing echinocandin dosing and susceptibil- ity breakpoint determination via in vivo pharmacody- namic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother 56: 5875-5882
100. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013a. Isa- vuconazole (BAL4815) pharmacodynamic target deter-mination in an in vivo murine model of invasive pulmo- nary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Che- mother 57: 6284-6289
101. Lepak AJ, Marchillo K, VanHecker J, Andes DR. 2013b. Im- pact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: Enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother 57: 5438-5447
102. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013c. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergil- lus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 57: 579-585
103. Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. 2013d. Isavuconazole pharmacodynamic target determi- nation for Candida species in an in vivo murine dissem- inated candidiasis model. Antimicrob Agents Chemother 57: 5642-5648
104. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. 1998. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 42: 1382-1386
105. Lewis RE, Klepser ME, Pfaller MA. 2000. In vitro pharma- codynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis 36: 101-105
106. Lewis RE, Wiederhold NP, Klepser ME. 2005. In vitro phar- macodynamics of amphotericin B, itraconazole, and vor-iconazole against Aspergillus, Fusarium, and Scedospo- rium spp. Antimicrob Agents Chemother 49: 945-951
107. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kon-toyiannis DP. 2007. Comparative analysis of amphoteri- cin B lipid complex and liposomal amphotericin B kinet- ics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 51: 1253-1258
108. Lewis RE, Albert ND, Kontoyiannis DP. 2008. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 61: 1140-1144
109. Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. 2011. Comparative in vivo dose-dependent activity of caspo-fungin and anidulafungin against echinocandin-suscep- tible and -resistant Aspergillus fumigatus. J Antimicrob Chemother 66: 1324-1331
110. Lewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, Kon- toyiannis DP. 2013. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. J Infect Dis 207: 834-841
111. Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, Kaw P, Shayegani M, Taber H, Miller MH. 1998. Pharmacody-namics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 42: 1105-1109
112. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persis- tence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49: 5058-5068
113. MacCallum DM, Whyte JA, Odds FC. 2005. Efficacy of cas-pofungin and voriconazole combinations in experimen- tal aspergillosis. Antimicrob Agents Chemother 49: 3697-3701
114. Manosuthi W, Chetchotisakd P, Nolen TL, Wallace D, Sung- kanuparph S, Anekthananon T, Supparatpinyo K, Pappas PG, Larsen RA, Filler SG, et al. 2010. Monitoring and impact of fluconazole serum and cerebrospinal fluid con- centration in HIV-associated cryptococcal meningitis- infected patients. HIV Med 11: 276-281
115. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010a. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 54: 860-865
116. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010b. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated asper- gillosis. Antimicrob Agents Chemother 54: 4758-4764
117. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, Sein T, Schaufele RL, Bacher J, Walsh TJ. 2006. Triazole-polyene antagonism in experimental inva- sive pulmonary aspergillosis: In vitro and in vivo corre- lation. J Infect Dis 194: 1008-1018
118. Mukherjee PK, Mohamed S, Chandra J, Kuhn D, Liu S, Antar OS, Munyon R, Mitchell AP, Andes D, Chance MR, et al. 2006. Alcohol dehydrogenase restricts the abil- ity of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infect Immun 74: 3804-3816
119. Munro CA, Selvaggini S, de Bruijn I, Walker L, Lenardon MD, Gerssen B, Milne S, Brown AJ, Gow NA. 2007. The PKC, HOG and Ca2þ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Micro- biol 63: 1399-1413
120. O’Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely MN, Harrison TS, et al. 2013. Pharmacodynamics of liposomal ampho- tericin B and flucytosine for cryptococcal meningoen- cephalitis: Safe and effective regimens for immunocom- promised patients. J Infect Dis 208: 351-361
121. Pai MP, Turpin RS, Garey KW. 2007. Association of flucon- azole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic pa- tients with candidemia. Antimicrob Agents Chemother 51: 35-39
122. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45: 883-893
123. Park BJ, Arthington-Skaggs BA, Hajjeh RA, Iqbal N, Ciblak MA, Lee-Yang W, Hairston MD, Phelan M, Plikaytis BD, Sofair AN, et al. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream iso- lates by correlation with therapeutic outcome. Antimi- crob Agents Chemother 50: 1287-1292
124. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. 2007. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother 59: 791-793
125. Peleg AY, Woods ML. 2004. Continuous and 4 h infusion of amphotericin B: A comparative study involving high-risk haematology patients. J Antimicrob Chemother 54: 803-808
126. Perfect JR, Savani DV, Durack DT. 1986. Comparison of itraconazole and fluconazole in treatment of cryptococ-cal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother 29: 579-583
127. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50: 291-322
128. Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Can- delario M, Field-Ridley A, Avila N, Bacher J, Walsh TJ. 2001. Antifungal activity and pharmacokinetics of po- saconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Cor- relation with galactomannan antigenemia. Antimicrob Agents Chemother 45: 857-869
129. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ. 2002. Anti-fungal efficacy of caspofungin (MK-0991) in experi- mental pulmonary aspergillosis in persistently neutrope- nic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 46: 12-23
130. Petraitis V, Petraitiene R, Groll AH, Bell A, Callender DP, Sein T, Schaufele RL, McMillian CL, Bacher J, Walsh TJ. 1998. Antifungal efficacy, safety, and single-dose phar- macokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 42: 2898-2905
131. Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ. 2001. Dosage-dependent antifungal efficacy of V- echinocandin (LY303366) against experimental flucona- zole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 45: 471-479
132. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hem- mings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against dis- seminated candidiasis and invasive pulmonary asper- gillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46: 1857-1869
133. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T, Groll AH, Bacher J, Avila NA, et al. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187: 1834-1843
134. Petraitis V, Petraitiene R, Solomon J, Kelaher AM, Murray HA, Mya-San C, Bhandary AK, Sein T, Avila NA, Base-vicius A, et al. 2006. Multidimensional volumetric imag- ing of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50: 1510-1517
135. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, et al. 2009. Combination therapy in treat- ment of experimental pulmonary aspergillosis: In vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and vor- iconazole by Bliss independence drug interaction analy- sis. Antimicrob Agents Chemother 53: 2382-2391
136. Pfaller MA, Diekema DJ. 2012. Progress in antifungal sus-ceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50: 2846-2856
137. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, Chaturvedi V, Ghannoum MA, Odds FC, Rinaldi MG, et al. 2006. Correlation of MIC with out- come for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol 44: 819-826
138. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommit-tee for Antifungal Testing. 2011a. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14: 164-176
139. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. 2011b. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveil- lance Program (2008 - 2009). Int J Antimicrob Agents 38: 65-69
140. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. 2012. Frequency of decreased sus-ceptibility and resistance to echinocandins among flu- conazole-resistant bloodstream isolates of Candida glab- rata. J Clin Microbiol 50: 1199-1203
141. Popolo L, Gualtieri T, Ragni E. 2001. The yeast cell-wall salvage pathway. Med Mycol 39 (Suppl 1): 111-121
142. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escala- tion regimens. Antimicrob Agents Chemother 46: 2546-2553
143. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-In- groff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. 1997. Development of inter- pretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro - in vivo correlation data for fluconazole, itraconazole, and can- dida infections. Subcommittee on Antifungal Suscep- tibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24: 235-247
144. Riddell J IV, Comer GM, Kauffman CA. 2011. Treatment of endogenous fungal endophthalmitis: Focus on new anti- fungal agents. Clin Infect Dis 52: 648-653
145. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. 2008. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 52: 3786-3788
146. Rodriguez MM, Pastor FJ, Sutton DA, Calvo E, Fothergill AW, Salas V, Rinaldi MG, Guarro J. 2010. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Anti- microb Agents Chemother 54: 1665-1669
147. Rodríguez-Tudela JL, Almirante B, Rodríguez-Pardo D, La- guna F, Donnelly JP, Mouton JW, Pahissa A, Cuenca-Es-trella M. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of pa- tients with mucosal candidiasis and candidemia. Antimi- crob Agents Chemother 51: 3599-3604
148. Rodvold KA, George JM, Yoo L. 2011. Penetration of anti- infective agents into pulmonary epithelial lining fluid: Focus on antibacterial agents. Clin Pharmacokinet 50: 637-664
149. Savani DV, Perfect JR, Cobo LM, Durack DT. 1987. Penetra- tion of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 31: 6-10
150. Schwartz S, Reisman A, Troke PF. 2011. The efficacy of vor- iconazole in the treatment of 192 fungal central nervous system infections: A retrospective analysis. Infection 39: 201-210
151. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. 2013a. Pharmacodynamics and dose-response relation-ships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 57: 1866-1871
152. Seyedmousavi S, Mouton JW, Verweij PE, Andes DR. 2013b. Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. Am J Respir Crit Care Med 188: 1033
153. Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW, Verweij PE. 2013c. In vitro interaction of voricona-zole and anidulafungin against triazole-resistant Asper- gillus fumigatus. Antimicrob Agents Chemother 57: 796-803
154. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. 2013d. Efficacy and pharmaco-dynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Che- mother 68: 385-393
155. Sheppard DC, Marr KA, Fredricks DN, Chiang LY, Doedt T, Filler SG. 2006. Comparison of three methodologies for the determination of pulmonary fungal burden in exper- imental murine aspergillosis. Clin Microbiol Infect 12: 376-380
156. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. 2011. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob Agents Che- mother 55: 2641-2647
157. Smith J, Andes D. 2008. Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 30: 167-172
158. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Ver- weij PE. 2008. Emergence of azole resistance in Aspergil- lus fumigatus and spread of a single resistance mecha- nism. PLoS Med 5: e219
159. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. 2005. Com- bination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 49: 830-832
160. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A. 1987. Toxicity of amphotericin B plus flucytosine in 194 pa- tients with cryptococcal meningitis. Am J Med 83: 236-242
161. Stevens DA, Espiritu M, Parmar R. 2004. Paradoxical effect of caspofungin: Reduced activity against Candida albi-cans at high drug concentrations. Antimicrob Agents Che-mother 48: 3407-3411
162. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51: 173-178
163. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accom- plished by increased cell wall chitin: Evidence for b-1,6- glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 50: 3160-3161
164. Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Warn PA, Felton TW, Perfect JR, et al. 2013. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: Implications for antifungal therapy and in vitro sus- ceptibility breakpoints. Antimicrob Agents Chemother 57: 2793-2800
165. Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, et al. 2009. Lipid formulations of amphotericin B signif- icantly improve outcome in solid organ transplant recip- ients with central nervous system cryptococcosis. Clin Infect Dis 49: 1721-1728
166. Szilagyi J, Foldi R, Bayegan S, Kardos G, Majoros L. 2012. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology. J Chemotherapy 24: 18-25
167. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S, Japan Invasive Mycosis Surveillance Study Group. 2004. Clinical factors associated with fluconazole resis- tance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 23: 380-388
168. Te Dorsthorst DT, Verweij PE, Meis JF, Punt NC, Mouton JW. 2013. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Asper- gillus isolates determined by two drug interaction mod- els. Antimicrob Agents Chemother 48: 2007-2013
169. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 55: 4782-4788
170. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA. 1994. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 34: 83-92
171. Utz JP. 1975. New drugs for the systemic mycoses: Flucyto- sine and clotrimazole. Bull NY Acad Med 51: 1103-1108
172. Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF. 2008. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantita- tive PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother 52: 2593-2598
173. van de Sande WW, Mathot RA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJ, Bakker-Woudenberg IA. 2009. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 53: 2005-2013
174. Vanstraelen K, Lagrou K, Maertens J, Wauters J, Willems L, Spriet I. 2013. The Eagle-like effect of echinocandins: What’s in a name? Expert Rev Anti Infect Ther 11: 1179-1191
175. Vazquez JA. 2008. Clinical practice: Combination antifungal therapy for mold infections: Much ado about nothing? Clin Infect Dis 46: 1889-1901
176. Vitale RG, Meis JF, Mouton JW, Verweij PE. 2003. Evalua- tion of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. J Antimicrob Chemother 52: 65-70
177. Vogelman BS, Craig WA. 1985. Postantibiotic effects. J Anti- microb Chemother 15 (Suppl A): 37-46
178. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 157: 287-298
179. Walsh TJ, Lee JW, Kelly P, Bacher J, Lecciones J, Thomas V, Lyman C, Coleman D, Gordee R, Pizzo PA. 1991. Anti- fungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-b-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother 35: 1321-1328
180. Walsh TJ, Petraitis V, Petraitiene R, Solomon J, Bacher JD, Greene L, Cotton M, Groll A, Roilides E, Avila N, et al. 2009. Diagnostic imaging of experimental invasive pul- monary aspergillosis. Med Mycol 47 (Suppl 1): S138-S145
181. Wanger A, Mills K, Nelson PW, Rex JH. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect ampho- tericin B-resistant Candida isolates. Antimicrob Agents Chemother 39: 2520-2522
182. Warn PA, Morrissey J, Moore CB, Denning DW. 2000. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother 44: 2664-2671
183. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: Mathematical modeling, importance of tissue concentrations, and im- pact of immune status on antifungal effect. Antimicrob Agents Chemother 53: 3453-3461
184. Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Greg- son L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wol-kowiez M, et al. 2012. Anidulafungin for neonatal hema- togenous Candida meningoencephalitis: Identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemo-ther 56: 708-714
185. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity. J Infect Dis 190: 1464-1471
186. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. 2005. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: Possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 49: 5146-5148
187. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of inva- sive pulmonary aspergillosis. Antimicrob Agents Chemo- ther 50: 469-473
188. Wiederhold NP, Najvar LK, Vallor AC, Kirkpatrick WR, Bo- canegra R, Molina D, Olivo M, Graybill JR, Patterson TF. 2008. Assessment of serum (1!3)-b-D-glucan concen- tration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 52: 1176-1178
189. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. 2011. Protein binding: Do we ever learn? Antimicrob Agents Chemother 55: 3067-3074